Addendum
Niraparib/abiraterone acetate (prostate cancer) – Addendum to Project A23-107
Report documents
-
Addendum
Niraparib/abiraterone acetate (prostate cancer) – Addendum to Project A23-107
Dossier assessment
Indication:
Adults with metastatic castration-resistant prostate cancer (mCRPC) and breast cancer susceptibility gene 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated
Result of dossier assessment:
- Patients with treatment-naive mCRPC without prior taxane-containing chemotherapy: Unchanged after addendum: hint of considerable added benefit
- Patients with treatment-naive mCRPC with prior taxane-containing chemotherapy: After addendum now: hint of minor added benefit
- Patients with pretreated mCRPC: Unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2024-05-02 A G-BA decision was published.
Project details
- Project no.
- A24-33
- Commission
- Commission awarded on 26.05.2024 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A24-33_en
Connected Projects
-
Dossier assessment
Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed